REalloys Raises $100 Million in New Stock Sale, But the 19% Crash Raises a Tougher Question: Can This Pre-Revenue Rare Earth Bet Afford to Keep Diluting Shareholders?

Shares of REalloys (ALOY) cratered 19.2% to $13.46 after the company disclosed a ~$100 million private placement — a sale of new stock directly to institutional investors — just three and a half months after it raised $50 million the same way. The sell-off vaporized roughly $200 million in market value in a single session and raises a pointed question: how much dilution can a company with almost no revenue absorb before the defense-supply thesis loses its grip on investors?

• Two Big Stock Sales in Four Months Signal a Cash-Hungry Operation. In March, REalloys closed an upsized $50 million public offering at $18.50 per share. Now it's back for roughly double that. The company says net proceeds will go toward "working capital and general corporate purposes" — vague language that gives management wide discretion. With trailing twelve-month revenue of just $2.55 million and a net loss margin of -4,326%, the company is burning cash far faster than it earns it, making serial stock sales practically inevitable.

• The Stock Was Already Overheated Before the Hammer Fell. ALOY surged from $16.61 on June 17 to $19.70 by June 22, partly on excitement around its upcoming Russell 3000 Index inclusion effective June 29, which boosts visibility with index funds and institutional investors. That kind of momentum makes a stock especially vulnerable to profit-taking when bad news hits. Short interest had already risen 45.6% from the prior reporting period, a sign some traders were betting against the rally.

• The Defense Deadline Is Real, But So Is the Execution Risk. Starting January 1, 2027, the Pentagon will be barred from buying weapons systems containing magnets made with Chinese rare earth materials — a hard compliance deadline for defense contractors. REalloys is positioning itself as one of the few non-Chinese suppliers. It holds exclusive access to 80% of output from a Canadian processing facility and targets initial commercial production in early 2027. But "on track" is not the same as proven. With approximately 61.2 million shares outstanding before this latest issuance, adding millions more shares pressures every existing investor's ownership stake while the company's path to meaningful revenue remains unproven.

• The Gap Between the Story and the Numbers Is Widening. REalloys has signed a flurry of supply agreements and letters of intent, yet its trailing revenue sits at $2.4 million against a net loss of $4.4 million. The $100 million raise buys time, but each dilutive round erodes the upside shareholders were banking on — making the January 2027 production deadline the single most important test of whether this stock is a defense-critical bargain or a capital-consuming gamble.